AstraZeneca says Imfinzi plus Imdelltra improved survival in SCLC
AstraZeneca PLC said Imfinzi plus Imdelltra showed statistically significant and highly clinically meaningful improvements in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer.
RNS Number: 8762T AstraZeneca PLC 08 September 2026 8 September 2026Imfinzi plus Imdelltra demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancerImfinzi is the fi…